![Qiang Chen](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Qiang Chen
Private Equity Investor chez
Heda Ventures
Profil
Qiang Chen is currently a Venture Partner at Heda Ventures.
Previously, in 2021-2022, he was the CMC Head, GM, and Co-CEO at Shanghai Genechem Co., Ltd. Dr. Chen holds a doctorate degree from New Mexico State University and an undergraduate degree from Xiamen University.
Postes actifs de Qiang Chen
| Sociétés | Poste | Début |
|---|---|---|
Heda Ventures
 Heda Ventures Investment ManagersFinance Heda Ventures invests in companies located in the United States. The firm focuses on companies operating in the fields of therapeutics, diagnostics, TMT and other revolutionary technologies sectors. It provides financing for seed and early stage capital requirements. | Private Equity Investor | - |
Anciens postes connus de Qiang Chen
| Sociétés | Poste | Fin |
|---|---|---|
Shanghai Genechem Co., Ltd.
 Shanghai Genechem Co., Ltd. BiotechnologyHealth Technology Provides scientific research service | Directeur Général | 01/08/2022 |
Formation de Qiang Chen
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
19
Relations au 1er degré
4
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
New Mexico State University
 New Mexico State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Xiamen University
 Xiamen University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Shanghai Genechem Co., Ltd.
Shanghai Genechem Co., Ltd. BiotechnologyHealth Technology Provides scientific research service | Health Technology |
Heda Ventures
Heda Ventures Investment ManagersFinance Heda Ventures invests in companies located in the United States. The firm focuses on companies operating in the fields of therapeutics, diagnostics, TMT and other revolutionary technologies sectors. It provides financing for seed and early stage capital requirements. | Finance |
